Cite
Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127-35doi: 10.1002/hep.27726.
Nelson, D. R., Cooper, J. N., Lalezari, J. P., Lawitz, E., Pockros, P. J., Gitlin, N., Freilich, B. F., Younes, Z. H., Harlan, W., Ghalib, R., Oguchi, G., Thuluvath, P. J., Ortiz-Lasanta, G., Rabinovitz, M., Bernstein, D., Bennett, M., Hawkins, T., Ravendhran, N., Sheikh, A. M., Varunok, P., Kowdley, K. V., Hennicken, D., McPhee, F., Rana, K., Hughes, E. A. (2015). All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (Baltimore, Md.), 61(4), 1127-35. https://doi.org/10.1002/hep.27726
Nelson, David R, et al. "All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study." Hepatology (Baltimore, Md.) vol. 61,4 (2015): 1127-35. doi: https://doi.org/10.1002/hep.27726
Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015 Apr;61(4):1127-35. doi: 10.1002/hep.27726. Epub 2015 Mar 10. PMID: 25614962; PMCID: PMC4409820.
Copy
Download .nbib